DovaVision UC Featured in Late Breaker Presentation at UEG Week 2025

Dova Health is proud to share that our AI-powered scoring tool, DovaVision UC, was featured in a Late Breaker presentation at UEG Week 2025 by Dr. Krisztina Gecse (Amsterdam UMC), with Prof. Geert D’Haens as a senior author.

‍

This post-hoc analysis applied DovaVision UC to the TITRATE trial dataset – a previously published randomized controlled trial (RCT) that had shown no benefit for personalized infliximab doing in acute severe ulcerative colitis (ASUC) when endoscopies were scored by human readers.

‍

When the trial data was rescored using AI, the results changed significantly. Personalized dosing was found to be superior to standard dosing in ASUC when endoscopies were scored by AI – an effect not observed with human scoring. This represents the first randomized controlled trial to demonstrate a difference in clinical outcomes depending on whether endoscopy was assessed by AI or human experts.

‍

These findings highlight the transformative potential of AI in gastroenterology – revealing therapeutic signals that might otherwise remain hidden and paving the way for more precise, data-driven trial designs in the future.

‍

Dova Health extends sincere gratitude to Dr. Krisztina Gecse, Prof. Geert D’Haens, and the entire TITRATE study team for leading this groundbreaking research. We are honoured that this work was selected as a Late Breaker at one of the most important global forums in gastroenterology.

‍

Although the full paper has yet to be published, you can view a high-level summary of the presentation here: Different outcomes of AI-read vs human-read endoscopies in the TITRATE study - Medical Conferences.

‍